LifeSci Capital Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $38
Citi Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Raises Target Price to $36
ArriVent BioPharma, Inc.: Strong Clinical Data and Improved Financial Outlook Prompt Buy Rating and Price Target Increase
ArriVent BioPharma Is Maintained at Buy by Goldman Sachs
Analysts Offer Insights on NA Companies: ArriVent BioPharma, Inc. (AVBP) and Rubrik, Inc. Class A (RBRK)
Oppenheimer Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Raises Target Price to $39
HC Wainwright & Co. Maintains Buy on ArriVent BioPharma, Raises Price Target to $36
ArriVent BioPharma Analyst Ratings
H.C. Wainwright Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Raises Target Price to $36
LifeSci Capital Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Raises Target Price to $38
Buy Rating Affirmed for ArriVent BioPharma on Firmonertinib's Promising Study Results and Market Potential
LifeSci Capital Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $33
H.C. Wainwright Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Raises Target Price to $30
A Quick Look at Today's Ratings for ArriVent BioPharma(AVBP.US), With a Forecast Between $30 to $35
Buy Rating Affirmed on ArriVent BioPharma's Strong Clinical Developments and Strategic Partnerships
ArriVent BioPharma Analyst Ratings
Oppenheimer Reiterates Outperform on ArriVent BioPharma, Maintains $35 Price Target
Oppenheimer Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $35
Jefferies Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $35
Analysts Offer Insights on NA Companies: ArriVent BioPharma, Inc. (AVBP) and Proficient Auto Logistics, Inc. (PAL)
No Data
No Data